The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

Feature Details Company Milestones and 2025 Catalysts Across Gene Therapy and Ophthalmic ProgramsNEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Dr.

Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat ...

The global Diabetic Retinopathy Market is valued at USD 9.1 Billion in 2024 and is projected to reach a value of USD 15.1 ...

Kodiak Sciences Inc.’s KOD share price has dipped by 10.63%, which has investors questioning if this is right time to buy.

India holds the unenviable position of being home to the world’s largest diabetic population, with nearly 100 million ...

Researchers have observed in a new study that stress hyperglycemia (SHR) ratio could be a useful predictor of neovascular ...

We will only include studies that refer to some measure of diabetic retinopathy treatment coverage in the abstract. As the use of anti-VEGF agents in the treatment of proliferative diabetic ...

Company management will be available for one-on-one meetings during the conference. If you are interested in arranging a meeting, please contact your conference representative or send an email to ...

Based on the results of dilated fundus examinations, the selected patients were categorized into the non-diabetic retinopathy group (296 cases in the NDR group) and the diabetic retinopathy group (102 ...

In December 2024, we reached agreement with the FDA under a SPA for a Phase 3 clinical trial evaluating APX3330, a novel, oral REF-1 inhibitor for the treatment of moderate to severe non-proliferative ...